nach oben

Erschienen in:

17.02.2017

Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin

Erschienen in: Cardiovascular Toxicology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The mechanisms underlying arrhythmia induced by the clinical use of azithromycin are poorly understood. We aimed to investigate the proarrhythmic effects of azithromycin using electrocardiogram (ECG) and ion channel models. In vivo and in vitro guinea pig ECG and current and voltage clamp recordings were carried out. Azithromycin at 114.6 mg/kg (three times the clinically relevant dose) reduced heart rate (HR) and prolonged the PR, QRS and rate-corrected QT (QTc) intervals of guinea pig ECG in vivo. In vitro technique revealed that azithromycin at 207.5 and 415 mg/L [five and ten times clinically relevant concentration (CRC)] reduced HR and prolonged the PR, QRS and QTc intervals in the isolated guinea pig heart ECG. Both arrhythmias presented bradyarrhythmic features, mainly with reduced HR and prolonged PR interval. Action potential analysis from the guinea pig cardiomyocytes indicated that azithromycin at 830 mg/L (20 times CRC) significantly prolonged the action potential durations at 50% (APD₅₀) and 90% (APD₉₀) of full repolarization levels with a rectangular pattern. Azithromycin significantly suppressed the L-type Ca²⁺ and Na⁺ currents from the left ventricular myocytes of guinea pig at 50% inhibiting concentrations (IC₅₀) of 942.5 ± 68.4 mg/L (22.7 times CRC) and 1123.0 ± 87.7 mg/L (27.1 times CRC), respectively. However, azithromycin at 50 times CRC (2075 mg/L) inhibited I_Kr current at an inhibition rate of 30.99 ± 5.23% with an undetectable IC₅₀. Azithromycin caused bradyarrhythmia primarily by inhibiting L-type Ca²⁺ and Na⁺ currents.

Lee, R. A., Guyton, A., Kunz, D., Cutter, G. R., & Hoesley, C. J. (2016). Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center. Journal of Hospital Medicine, 11, 15–20.CrossRefPubMed

Huang, B. H., Wu, C. H., Hsia, C. P., & Yin Chen, C. (2007). Azithromycin-induced torsade de pointes. Pacing and Clinical Electrophysiology, 30, 1579–1582.CrossRefPubMed

Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012). Azithromycin and the risk of cardiovascular death. The New England Journal of Medicine, 366, 1881–1890.CrossRefPubMedPubMedCentral

Rao, G. A., Mann, J. R., Shoaibi, A., Bennett, C. L., Nahhas, G., Sutton, S. S., et al. (2014). Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Annals of Family Medicine, 12, 121–127.CrossRefPubMedPubMedCentral

Chou, H. W., Wang, J. L., Chang, C. H., Lai, C. L., Lai, M. S., & Chan, K. A. (2015). Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: A Taiwanese nationwide study. Clinical Infectious Diseases, 2015(60), 566–577.CrossRef

Tilelli, J. A., Smith, K. M., & Pettignano, R. (2006). Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy, 26, 147–150.CrossRefPubMed

Nilsson, M. F., & Webster, W. S. (2014). Effects of macrolide antibiotics on rat embryonic heart function in vitro. Birth Defects Research Part B, Developmental and Reproductive Toxicology, 101, 189–198.CrossRefPubMed

FDA Drug Safety Communication. Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. http://www.fda.gov/drugs/drugsafety/ucm341822.htm. Accessed March 12, 2013.

Maisch, N. M., Kochupurackal, J. G., & Sin, J. (2014). Azithromycin and the risk of cardiovascular complications. Journal of Pharmacy Practice, 27, 496–500.CrossRefPubMed

10.

Granowitz, E. V., Tabor, K. J., & Kirchhoffer, J. B. (2000). Potentially fatal interaction between azithromycin and disopyramide. Pacing and Clinical Electrophysiology, 23, 1433–1435.CrossRefPubMed

11.

Samarendra, P., Kumari, S., Evans, S. J., Sacchi, T. J., & Navarro, V. (2001). QT prolongation associated with azithromycin/amiodarone combination. Pacing and Clinical Electrophysiology, 24, 1572–1574.CrossRefPubMed

12.

Cocco, G., & Jerie, P. (2015). Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: An unexpected dangerous interaction. Cardiovascular Toxicology, 15, 104–106.CrossRefPubMed

13.

Winton, J. C., & Twilla, J. D. (2013). Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. The American Journal of the Medical Sciences, 345, 160–162.CrossRefPubMed

14.

Niedrig, D., Maechler, S., Hoppe, L., Corti, N., Kovari, H., & Russmann, S. (2016). Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: Administration of interacting co-medication and QT prolongation. European Journal of Clinical Pharmacology, 72, 859–867.CrossRefPubMed

15.

Howard, P. A. (2013). Azithromycin-induced proarrhythmia and cardiovascular death. The Annals of Pharmacotherapy, 47, 1547–1551.CrossRefPubMed

16.

Ohara, H., Nakamura, Y., Watanabe, Y., Cao, X., Yamazaki, Y., Izumi-Nakaseko, H., et al. (2015). Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes. Cardiovascular Toxicology, 15, 232–240.CrossRefPubMed

17.

Trac, M. H., McArthur, E., Jandoc, R., Dixon, S. N., Nash, D. M., Hackam, D. G., et al. (2016). Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. Canadian Medical Association Journal, 188, E120–E129.CrossRefPubMedPubMedCentral

18.

Svanström, H., Pasternak, B., & Hviid, A. (2013). Use of azithromycin and death from cardiovascular causes. The New England Journal of Medicine, 368, 1704–1712.CrossRefPubMed

19.

Albert, R. K., & Schuller, J. L. (2014). COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. American Journal of Respiratory and Critical Care Medicine, 189, 1173–1180.CrossRefPubMedPubMedCentral

20.

Fossa, A. A., Wisialowski, T., Duncan, J. N., Deng, S., & Dunne, M. (2007). Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. The American Journal of Tropical Medicine and Hygiene, 77, 929–938.PubMed

21.

Thomsen, M. B., Beekman, J. D., Attevelt, N. J., Takahara, A., Sugiyama, A., Chiba, K., et al. (2006). No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. British Journal of Pharmacology, 149, 1039–1048.CrossRefPubMedPubMedCentral

22.

Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., et al. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. The Journal of Pharmacology and Experimental Therapeutics, 303, 218–225.CrossRefPubMed

23.

Reagan-Shaw, S., Nihal, M., & Ahmad, N. (2008). Dose translation from animal to human studies revisited. FASEB Journal, 22, 659–661.CrossRefPubMed

24.

Chen, L., Titch, T., Luo, Z., Xu, Y., Li, X., Huang, F., et al. (2012). Confirmation of a proarrhythmic risk underlying the clinical use of common Chinese herbal intravenous injections. Journal of Ethnopharmacology, 142, 829–835.CrossRefPubMed

25.

Chen, L., Wang, L., Xu, B., Ni, G., Yu, L., Han, B., et al. (2009). Mechanisms of alpha1-adrenoceptor mediated QT prolongation in the diabetic rat heart. Life Sciences, 84, 250–256.CrossRefPubMed

26.

Salimi, A., Eybagi, S., Seydi, E., Naserzadeh, P., Kazerouni, N. P., & Pourahmad, J. (2016). Toxicity of macrolide antibiotics on isolated heart mitochondria: A justification for their cardiotoxic adverse effect. Xenobiotica, 46, 82–93.CrossRefPubMed

27.

Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed

28.

Matzneller, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., et al. (2013). Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents and Chemotherapy, 57, 1736–1742.CrossRefPubMedPubMedCentral

Titel: Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin
Publikationsdatum: 17.02.2017
Erschienen in: Cardiovascular Toxicology / Ausgabe 4/2017
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-017-9401-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Ultrafine Particulate Matter Increases Cardiac Ischemia/Reperfusion Injury via Mitochondrial Permeability Transition Pore

Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP

Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism

Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone

Flecainide-Induced Left Ventricular Dysfunction: Fact or Fiction?

In Utero Exposure of Hyperlipidemic Mice to Diesel Exhaust: Lack of Effects on Atherosclerosis in Adult Offspring Fed a Regular Chow Diet